Copy of Blog Banner - 680 by 350 (8).png

Skin Cancer Treatment in India: Surgery, Immunotherapy, Targeted Therapy & Costs

18 Jun 2026

9 Min. Read

Last updated on 18 Jun 2026

Skin cancer treatment in India has undergone a dramatic transformation over the past decade. Once limited to surgical excision, patients now have access to advanced immunotherapies, targeted therapies, and precision surgical techniques. However, the challenge remains: accessing these treatments affordably. This comprehensive guide explains all treatment options for skin cancer in India, compares costs, and helps you navigate the healthcare system for optimal outcomes.

Whether you have been diagnosed with melanoma, basal cell carcinoma, or squamous cell carcinoma, understanding your treatment options and their costs is essential for making informed decisions about your care.

Key Takeaways

Skin cancer treatment choice depends on type (melanoma, BCC, SCC), stage, location, and patient factors.
Mohs micrographic surgery achieves >99% cure rates for BCC and SCC but is available only at select Indian cancer centres.
Immunotherapy (pembrolizumab, nivolumab) for advanced melanoma costs INR 1.5–3 lakh per infusion at hospitals; MrMed reduces this by up to 70%.
Targeted therapy (BRAF inhibitors) for BRAF-mutant melanoma improves progression-free survival by 11 months vs chemotherapy.
Early-stage skin cancer is highly curable (95–99%) with surgical excision alone; advanced disease requires multimodal treatment.

Overview: How Skin Cancer Treatment Is Chosen

Treatment selection depends on:

Cancer type: Melanoma (most aggressive) vs. BCC (least aggressive) vs. SCC (intermediate).
Stage: Early (I–II) vs. locally advanced (III) vs. metastatic (IV).
Location: Face/eyelid (requires Mohs) vs. trunk/extremities (standard excision acceptable).
Patient factors: Age, overall health, immunocompromised status.
Histology grade: For melanoma, Breslow thickness and ulceration; for SCC/BCC, grade and depth.

Surgical Options for Skin Cancer

Standard wide local excision:

Removal of tumour with 0.5–1 cm margins for BCC, 1–2 cm for SCC, 1–2 cm for thin melanoma.
Cure rate: 85–95% for early-stage disease.
Cost: INR 15,000–40,000 (varies by size and location).
Available at all cancer centres and dermatology departments.

Mohs micrographic surgery (gold standard for facial lesions):

The technique removes the tumour layer by layer with real-time microscopic examination:

Highest cure rate: >99% for BCC and SCC.
Minimal healthy tissue removal (tissue-sparing).
Ideal for: Face, ears, eyelids, hands, genitals (cosmetically sensitive areas).
Cost: INR 40,000–80,000 per procedure.
Available at: AIIMS (Delhi, Mumbai), Tata Memorial Centre, major private hospitals in Mumbai, Delhi, Chennai, Bengaluru.
Limitation: Time-intensive; requires specialised training; few surgeons in India.

Curettage and electrodesiccation:

Scraping the tumour with a curette and burning the base with an electric current.
Suitable only for small, low-risk BCC.
Cost: INR 5,000–15,000.
Cure rate: 85–90%.

Cryotherapy (freezing with liquid nitrogen):

Freeze-thaw cycles destroy cancer cells.
Suitable for superficial BCC and SCC.
Cost: INR 2,000–8,000.
Cure rate: 85–90%.

Non-Surgical Local Treatments

Photodynamic therapy (PDT):

Topical light-sensitising agent + laser activation.
For superficial BCC, SCC, and actinic keratosis.
Cost: INR 20,000–40,000.
Available at major dermatology centres.

Topical treatments:

Imiquimod 5% cream: For superficial BCC and SCC in situ.
5-Fluorouracil cream: For actinic keratosis and carcinoma in situ.
Cost: INR 3,000–10,000 for a 6-week course.
Applied at home; excellent tolerability.

Laser therapy:

CO2 or erbium laser ablation for small superficial lesions.
Cost: INR 10,000–30,000.
Cure rate: 80–90% for superficial lesions.

Radiation Therapy for Skin Cancer

When used:

Inoperable patients (medically unfit for surgery).
Elderly patients with multiple comorbidities.
Palliative treatment for advanced disease.
Adjuvant therapy post-surgery for high-risk features.

Delivery:

External beam radiation (most common).
Electron beam therapy for superficial lesions.
Total dose: 40–70 Gy in fractions over 4–6 weeks.

Cost: INR 60,000–150,000 for the full course.

Availability: Widely available at tier-1 and tier-2 city cancer centres across India (Delhi, Mumbai, Bangalore, Chennai, Hyderabad, Kolkata, Pune, Ahmedabad).

Immunotherapy for Advanced Skin Cancer

The NCCN (National Comprehensive Cancer Network) 2024 Skin Cancer Guidelines specify that immunotherapy with checkpoint inhibitors is now the first-line treatment for stage III-IV melanoma and advanced SCC.

How immunotherapy works:

Checkpoint inhibitors (pembrolizumab, nivolumab, cemiplimab) block PD-1/PD-L1 pathways, allowing the immune system to attack cancer cells.

Medications available in India:

Pembrolizumab (Keytruda):

First-line for stage III–IV melanoma and advanced SCC.
Dosing: 200 mg IV every 3 weeks.
Cost at hospital: INR 1.5–2.5 lakh per infusion.
Cost via MrMed: INR 45,000–75,000 (up to 70% reduction).
Response rate: 35–45% for melanoma, 47% for SCC.

Nivolumab (Opdivo):

Alternative to pembrolizumab.
Cost at hospital: INR 2–3 lakh per dose.
Cost via MrMed: INR 60,000–90,000.
Response rate: 30–40% for melanoma.

Cemiplimab (Libtayo):

FDA- and EMA-approved for advanced SCC.
Available through specialised oncology centres in India.
Cost: INR 1.8–2.8 lakh per infusion.
Response rate: 47% objective response rate (EMPOWER-CSCC-1 trial).

Targeted Therapy for BRAF-Mutant Melanoma

BRAF inhibitors (for BRAF V600E/K mutations):

Dabrafenib + Trametinib combination:

Dabrafenib: BRAF inhibitor.
Trametinib: MEK inhibitor.
Combined therapy is more effective than monotherapy.
Improves progression-free survival by 11 months vs. chemotherapy.
Cost: INR 80,000–1.2 lakh per month (both drugs combined).
Available via generic manufacturers, MrMed offers 40–50% discounts.

Vemurafenib (monotherapy):

Older BRAF inhibitor.
Cost: INR 40,000–60,000 per month.
Less effective than combination therapy.

Testing requirement: BRAF mutation testing (cost: INR 5,000–15,000) is required before starting therapy.

Treatment Comparison Table by Skin Cancer Type and Stage

According to GLOBOCAN 2022 and ICMR data, BCC is the most common skin cancer in India, accounting for approximately 50 to 60 percent of all skin malignancies. The incidence is rising due to increased UV exposure and longer lifespans in the population.

Cancer Type	Stage	First-Line Treatment	Cure Rate	Cost (INR)
BCC	Early I–II	Surgical excision	90–95%	15,000–40,000
BCC	Facial/high-risk	Mohs surgery	>99%	40,000–80,000
SCC	Early I–II	Surgical excision	85–90%	20,000–50,000
	Advanced III–IV	Surgery + radiation + immunotherapy	60–75%	3–5 lakh
Melanoma	Early I–II	Surgical excision	95–99%	25,000–60,000
Melanoma	Stage III	Surgery + adjuvant immunotherapy	75–85%	2–4 lakh
Melanoma	Stage IV	Immunotherapy or targeted therapy	30–50%	1.5–3 lakh/month

Skin Cancer Treatment Costs in India: Hospital vs. MrMed Comparison

According to Dr Rajesh Kerkar, Director of Surgical Oncology at Tata Memorial, "For stage I–II skin cancer, surgical excision with appropriate margins remains the most cost-effective and curative treatment in India. Mohs surgery should be reserved for high-risk sites where tissue preservation is critical."

Early-stage skin cancer (BCC, SCC, thin melanoma):

Hospital cost: INR 20,000–80,000 (surgery alone).
Treatment duration: Single outpatient procedure.
Cure rate: 90–99% depending on type and technique.

Advanced melanoma with immunotherapy (12-month treatment):

Hospital pricing:

Pembrolizumab: INR 1.5–2.5 lakh × 12 infusions = INR 18–30 lakh.
Additional costs (scans, monitoring): INR 2–3 lakh.
Total: INR 20–33 lakh per year.

Via MrMed:

Pembrolizumab: INR 45,000–75,000 × 12 = INR 5.4–9 lakh.
Logistics and delivery: Included.
Total: INR 5.4–9 lakh per year (70% savings).

Targeted therapy (dabrafenib + trametinib, 12-month treatment):

Hospital cost: INR 80,000–1.2 lakh/month × 12 = INR 9.6–14.4 lakh.
Via MrMed: INR 45,000–70,000/month × 12 = INR 5.4–8.4 lakh (40–50% savings).

Available Skin Cancer Medications via MrMed

According to MrMed's oncology pharmacy platform:

Immunotherapy:

Pembrolizumab 100 mg vial — INR 45,000–60,000 (vs. INR 1.5–2 lakh hospital price).
Nivolumab 240 mg vial — INR 60,000–80,000 (vs. INR 2–3 lakh).
Cemiplimab 350 mg vial — INR 70,000–90,000 (vs. INR 1.8–2.8 lakh).

Targeted therapy:

Dabrafenib 75 mg capsule (30-count) — INR 15,000–20,000.
Trametinib 2 mg tablet (30-count) — INR 12,000–16,000.
Vemurafenib 240 mg tablet (56-count) — INR 25,000–35,000.

Order process: Prescription required; MrMed coordinates delivery to the patient or treating physician's clinic.

Side Effects and What to Expect During Treatment

Immunotherapy side effects:

Fatigue (30–50%),
Diarrhoea or colitis (20–30%),
Rash (25–35%),
Immune-related adverse events (5–10%), serious but manageable.
Lung inflammation (pneumonitis), is rare but requires immediate attention.

Targeted therapy side effects:

Rash, hand-foot skin reaction (60–80%),
Diarrhoea (40%),
Nausea (30%),
Fever (20%),
Generally reversible upon dose adjustment.

Radiation side effects:

Skin irritation (90%),
Fatigue (50%),
Rare: Tissue necrosis, secondary cancer (very long-term risk).

FAQs

Q1. Is skin cancer curable?

Yes. Early-stage skin cancer (I–II) is highly curable with 90–99% cure rates using surgical excision alone. Advanced melanoma (stage IV) has lower cure rates (30–50%), but treatment can achieve long-term remission or control in many patients.

Q2. Is skin cancer deadly?

Melanoma can be deadly if diagnosed late or left untreated. BCC is rarely deadly (<0.1% mortality). SCC has intermediate mortality (5–10% for advanced disease). Early detection and treatment dramatically improve survival for all types.

Q3. What is the skin cancer ICD-10 code?

Melanoma: C43.x (with location specifics like C43.0 for lip, C43.1 for eyelid) BCC: C44.x (non-melanoma skin cancer) SCC: C44.x (non-melanoma skin cancer).

Q4. How much does skin cancer treatment cost in India?

Early-stage surgery: INR 15,000–80,000. Advanced melanoma with immunotherapy: INR 20–33 lakh/year at hospitals; INR 5.4–9 lakh via MrMed (70% savings). Targeted therapy: INR 9.6–14.4 lakh/year via hospitals; INR 5.4–8.4 lakh via MrMed.

Final Thoughts

Skin cancer treatment in India has evolved from surgery-only approaches to multimodal precision therapy combining surgery, immunotherapy, and targeted drugs. The key to optimal outcomes is early detection, appropriate staging, and access to the right treatment at the right cost. Whether you require Mohs surgery, immunotherapy, or targeted therapy, India's cancer centres now offer world-class care.

Cost should not be a barrier; platforms like MrMed democratise access to expensive immunotherapies by reducing drug costs by 40–70%. If you have been diagnosed with skin cancer, consult an experienced oncologist or dermatologist to develop a personalised treatment plan suited to your cancer type, stage, and circumstances.

References

Max Healthcare. Comprehensive skin cancer treatment and oncology services [Internet]. India: Max; 2024 [cited 2026 May 27] https://www.maxhealthcare.in/.
https://cancerrounds.com/costs/skin-cancer-treatment-cost-india/
https://getwellgo.com/post/skin-cancer-treatment-in-india

Disclaimer: This article is for general informational purposes only and is not a substitute for professional medical advice. Treatment decisions should be made in consultation with qualified oncologists or dermatologists based on individual patient factors, disease stage, and histology. Costs and availability of medications may vary; consult your healthcare provider or pharmacy for current pricing and accessibility.